Crucially, by comparing the EV proteomes of high‐risk AML patients to those of healthy donors, we found that all proteins assigned to ErbB signalling were upregulated in EVs from AML patients, further corroborating our findings. The gene discussed is EGFR; the disease is acute myeloid leukemia.